Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of KVD824 in Healthy Volunteers
NCT05178355Phase 1Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KVD824 in hereditary angioedema (HAE) (14 arms), sponsored by KalVista Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events, Vital signs and 2 more. Started Feb 2019; status: completed.
02
Drugs
KVD824
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05178355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178355.